Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes

Vaccine

Volumn 24, Issue 26, 2006, Pages 5516-5525

  Palmer, Kenneth E ^a   Benko, Ann ^b   Doucette, Sarah A ^a   Cameron, Terri I ^a   Foster, Tiffany ^a   Hanley, Kathleen M ^a   McCormick, Alison A ^a   McCulloch, Michael ^a   Pogue, Gregory P ^a   Smith, Mark L ^a   Christensen, Neil D ^b  

^a Large Scale Biology Corporation   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

CRPV; L2; Papilloma; Protection; Rabbit; Recombinant virus; TMV; Vaccination

Indexed keywords

CAPSID PROTEIN; COTTONTAIL RABBIT PAPILLOMAVIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; RABBIT ORAL PAPILLOMAVIRUS VACCINE; RECOMBINANT TOBACCO MOCAIC VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SERUM; SKIN PAPILLOMA; STATISTICAL SIGNIFICANCE; TOBACCO MOSAIC VIRUS; VIRION; VIRUS CAPSID; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; EPITOPES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RABBITS; SKIN DISEASES, INFECTIOUS; TOBACCO MOSAIC VIRUS; VIRAL VACCINES;

EID: 33744825989     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.058     Document Type: Article

References (39)

1. Breitburd F., Kirnbauer R., Hubbert N.L., et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 (1995) 3959-3963
2. Kirnbauer R., Chandrachud L.M., O'Neil B.W., et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219 (1996) 37-44
3. Donnelly J.J., Martinez D., Jansen K.U., Ellis R.W., Montgomery D.L., and Liu M.A. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 173 2 (1996) 314
4. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. New England J Med 347 21 (2002) 1645-1651
5. Villa L.L. Vaccines against papillomavirus infections and disease. Salud Publica de Mexico 45 (2003) S443-S448
6. Billich A. HPV vaccine MedImmune/GlaxoSmithKline. Curr Opin Investig Drugs 4 2 (2003) 210-213
7. Christensen N.D., Reed C.A., Cladel N.M., Han R., and Kreider J.W. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70 (1996) 960-965
8. Roden R.B., Yutzy W.H., Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270 2 (2000) 254-257
9. Embers M.E., Budgeon L.R., Pickel M., and Christensen N.D. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 76 19 (2002) 9798-9805
10. Gerlich W.H., Krüger D.H., and Ulrich R. Chimeric virus-like particles as vaccines. Intervirology 39 (1996) 7-8
11. Müller M., Zhou J.A., Reed T.D., et al. Chimeric papillomavirus-like particles. Virology 234 (1997) 93-111
12. Chackerian B., Lowy D.R., and Schiller J.T. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci USA 96 5 (1999) 2373-2378
13. Slupetzky K., Shafti-Keramat S., Lenz P., et al. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 82 Pt 11 (2001) 2799-2804
14. Varsani A., Williamson A.L., de Villiers D., Becker I., Christensen N.D., and Rybicki E.P. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 77 (2003) 8386-8393
15. Li Q., Cao C., Chackerian B., et al. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci 5 1 (2004) 21
16. Lin Y.-L., Borenstein L.A., Ahmed R., and Wettstein F.O. Cottontail rabbit papillomavirus L1 protein-based vaccines: Protection is achieved only with a full-length, non-denatured product. J Virol 67 (1993) 4154-4162
17. Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., and Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73 7 (1999) 6188-6190
18. Gooding Jr. G.V., and Hebert T.T. A simple technique for purification of tobacco mosaic virus in large quantities. Phytopathology 57 11 (1967) 1285
19. Karas M., and Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 Da. Anal Chem 60 20 (1988) 2299-2301
20. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 5259 (1970) 680-685
21. Christensen N.D., Cladel N.M., Reed C.A., et al. Laboratory production of infectious stocks of rabbit oral papillomavirus. J Gen Virol 77 (1996) 1793-1798
22. Christensen N.D., Cladel N.M., Reed C.A., and Han R. Rabbit oral papillomavirus complete genome sequence and immunity following genital infection. Virology 269 2 (2000) 451-461
23. Embers M.E., Budgeon L.R., Culp T.D., Reed C.A., Pickel M., and Christensen N.D. Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins. Vaccine 22 (2004) 670-680
24. Christensen N.D., Höpfl R., DiAngelo S.L., et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 75 (1994) 2271-2276
25. Pastrana D.V., Buck C.B., Pang Y.Y., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 2 (2004) 205-216
26. Pastrana D.V., Gambhira R., Buck C.B., et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 2 (2005) 365-372
27. Kawana K., Yasugi T., Kanda T., et al. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21 27-30 (2003) 4256-4260
28. Filner B., and Marcus A. TMV coat protein synthesis in vivo: analysis of the N-terminal acetylation. Virology 61 2 (1974) 537-546
29. Morimoto Y., Saga K., Bando M., and Takahashi M. Invitro DNA synthesis of keratinocytes in normal human skin, psoriasis, seborrhoeic keratosis, Bowen's disease and basal cell carcinoma. Br J Derm 125 (1991) 9-13
30. Christensen N.D., Kreider J.W., Kan N.C., and DiAngelo S.L. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181 (1991) 572-579
31. McGarvie G.M., Chandrachud L.M., Gaukroger J.M., et al. Vaccination of cattle with L2 protein prevents BPV-4 infection. In: Stanley M.A. (Ed). Immunology of Human Papillomavirus (1994), Plenum Press, New York and London 283
32. Chandrachud L.M., Grindlay G.J., McGarvie G.M., et al. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology 211 (1995) 204-208
33. Gaukroger J.M., Chandrachud L.M., O'Neil B.W., Grindlay G.J., Knowles G., and Campo M.S. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus neutralizing antibodies. J Gen Virol 77 (1996) 1577-1584
34. Campo M.S., O'Neil B.W., Grindlay G.J., Curtis F., Knowles G., and Chandrachud L. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology 234 (1997) 261-266
35. Roden R.B., Weissinger E.M., Henderson D.W., et al. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol 68 11 (1994) 7570-7574
36. Munoz N., Bosch F.X., De Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England J Med 348 6 (2003) 518-527
37. Arntzen C.J. Vaccines, Preventing Disease and Protecting Health. In: de Quadros C. (Ed). Oral Vaccines from Transgenic Plants (2005), Pan American Health Organization 256-262
38. Grill L.K., Palmer K.E., and Pogue G.P. Use of plant viruses for production of plant-derived vaccines. Crit Rev Plant Sci 24 4 (2005) 309-323
39. Smith ML, Lindbo JA, Dillard-Telm S, Brosio PM, Lasnik AB, McCormick AA, Nguyen LV, and Palmer KE. Modified Tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology, (in press).